Cargando…

Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes

INTRODUCTION: Myelodysplastic syndromes encompass a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, refractory cytopenia and a tendency to progress toward acute myeloid leukemia. The accumulation of genetic alterations is closely associated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Machado-Neto, João Agostinho, Traina, Fabiola, Lazarini, Mariana, de Melo Campos, Paula, Pagnano, Katia Borgia Barbosa, Lorand-Metze, Irene, Costa, Fernando Ferreira, Olalla Saad, Sara T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2011
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109377/ https://www.ncbi.nlm.nih.gov/pubmed/21789382 http://dx.doi.org/10.1590/S1807-59322011000500014

Ejemplares similares

IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes
por: de Melo Campos, Paula, et al.
Publicado: (2018)

Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else
por: de Melo Campos, Paula, et al.
Publicado: (2014)

Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2(V617F) cells
por: Machado-Neto, João Agostinho, et al.
Publicado: (2015)

PTK2 and PTPN11 expression in myelodysplastic syndromes
por: Lazarini, Mariana, et al.
Publicado: (2013)

Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors
por: Reis-Alves, Suiellen C, et al.
Publicado: (2015)

Immunophenotyping in Myelodysplastic Syndromes Can Add Prognostic Information to Well-Established and New Clinical Scores
por: Reis-Alves, Suiellen C., et al.
Publicado: (2013)

Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up
por: PAGNANO, KATIA BORGIA BARBOSA, et al.
Publicado: (2016)

Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2015)

Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms
por: Scopim-Ribeiro, Renata, et al.
Publicado: (2016)

Mutation Analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese Patients with Myeloproliferative Neoplasms
por: Wang, Min, et al.
Publicado: (2014)

Stathmin 1 in normal and malignant hematopoiesis
por: Machado-Neto, João Agostinho, et al.
Publicado: (2014)

Reactive oxygen species overload promotes apoptosis in JAK2V617F-positive cell lines()
por: Machado-Neto, João Agostinho, et al.
Publicado: (2016)

IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2(V617F)-positive myeloproliferative neoplasms
por: de Melo Campos, Paula, et al.
Publicado: (2016)

Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2019)

A simple score derived from bone marrow immunophenotyping is important for prognostic evaluation in myelodysplastic syndromes
por: Vido-Marques, J. R., et al.
Publicado: (2020)

Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center
por: Moura, Ariella Cássia de, et al.
Publicado: (2019)

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
por: Naseem, Shano, et al.
Publicado: (2021)

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
por: Rocquain, Julien, et al.
Publicado: (2010)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
por: Sorcini, D, et al.
Publicado: (2023)

Using Antigen Expression of Leukemic Cells for a Fast Screening of Acute Promyelocytic Leukemia by Flow Cytometry
por: Ceni-Silva, Vitória, et al.
Publicado: (2021)

FLT3-ITD, NPM1, and DNMT3A Gene Mutations and Risk Factors in Normal Karyotype Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients in Upper Northern Thailand
por: Mevatee, Piyanan, et al.
Publicado: (2017)

Part 2: Myelodysplastic syndromes – classification systems
por: Lorand-Metze, Irene, et al.
Publicado: (2018)

Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2021)

Inflammatory picture of Philadelphia-negative myeloproliferative neoplasms()
por: Pagnano, Katia Borgia Barbosa
Publicado: (2018)

BCR-ABL1 level monitoring in chronic myeloid leukemia by real time polymerase chain reaction in Brazil – not so real()
por: Pagnano, Katia Borgia Barbosa
Publicado: (2017)

Computerized texture analysis of atypical immature myeloid precursors in patients with myelodysplastic syndromes: an entity between blasts and promyelocytes
por: Vido, Joyce R, et al.
Publicado: (2011)

Mutation of NPM1 and FLT3 Genes in Acute Myeloid Leukemia and Their Association with Clinical and Immunophenotypic Features
por: Chauhan, Pradeep Singh, et al.
Publicado: (2013)

FLT3 and NPM-1 mutations in a cohort of acute promyelocytic leukemia patients from India
por: Swaminathan, Suchitra, et al.
Publicado: (2014)

Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients
por: Moualla, Yahia, et al.
Publicado: (2022)

Stathmin 1 expression in plasma cell neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2017)

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response
por: Machado, Melissa Pereira, et al.
Publicado: (2011)

Examination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland
por: Koczkodaj, Dorota, et al.
Publicado: (2016)

Clinico-Haematologic association and prognostic relevance of NPM1 and FLT3-ITD mutations in acute Myeloid Leukaemia
por: Mahmood, Rafia, et al.
Publicado: (2019)

GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
por: Sportoletti, Paolo, et al.
Publicado: (2019)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014)

Treatment Outcome of Acute Promyelocytic Leukemia with Modified Aida Protocol
por: Pagnano, Kátia B. Barbosa, et al.
Publicado: (2010)

Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
por: Benites, Bruno Deltreggia, et al.
Publicado: (2013)

Mutations in AML with a normal karyotype: NPM1 and FLT3-ITD, ready to use as a key prognosticator?
por: Kim, Hee-Je
Publicado: (2010)

Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o54a001i5t43sb3v8fn1pi65rr